Month: June 2025

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association’s 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland. Details of the presentations are as follows:Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study Presenter: Michael E. Manning, M.D.Format: Poster Presentation, #22Date, time:...

SINGAPORE and SHANGHAI, June 27, 2025 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World” or the “Company”), a key player in the global hotel industry, today announced that the 2025 annual general meeting of the Company (the “AGM”) was held on June 27, 2025. During the AGM, the following proposed resolutions were duly passed:the ordinary resolution as set out in the notice of the AGM dated May 8, 2025 (the “Notice of AGM”) regarding the ratification of appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP as auditor of the Company for 2025 and the authorization for the directors of the Company to determine the remuneration of the auditor; the ordinary resolution as set out in the Notice of AGM regarding re-election of Ms. Jie Zheng (appointed by the board of directors of the Company...

June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AKITM (NGAL) for the US market. This purchase order is to service US hospitals through BioPorto’s distribution relationship with Roche Diagnostics. Currently, ProNephro AKITM (NGAL) has FDA 510(k) marketing clearance for Roche’s cobas® c501 analyzers, that are broadly available in standard medical laboratories and hospitals. Peter Mørch Eriksen, BioPorto’s Group...

COMPANY ANNOUNCEMENT NO. 13-2025 FLSmidth & Co. A/S 26 June 2025 Copenhagen, DenmarkThis company announcement discloses the data of transaction(s) made in FLSmidth & Co. A/S (“FLSmidth”) shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to FLSmidth and have given FLSmidth power of attorney on their behalf to publish trading in FLSmidth shares by the company’s board members, executives and their associated persons. Mikko Keto, Chief Executive Officer of FLSmidth, has reported the sale of 20,000 shares at a total consideration of DKK 7,864,651.60 and now holds a total of 23,484 shares in the company. A statement showing more...

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will present at the following investor conferences: mwb online Health Care ConferenceDate: July 1, 2025Presentation Time: 12:00 pm CEST Attendees: Frank Weber, CEO; Julia Neugebauer, COOVirtual conferenceLink to conference https://research-hub.de/events/registration/2025-07-01-12-00/VVY-NA H.C. Wainwright 4th Annual Kidney Virtual ConferenceDate: July 14, 2025 Presentation Time: 3:00 pm CEST / 9:00 am EDTAttendees: Frank Weber, CEO; Julia Neugebauer, COOVirtual...

Press Release dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 27, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital. This share repurchase program started for an initial €500 million and will now be increased to €1 billion, following the completion of the previously announced sale of dsm-firmenich’s stake in the Feed Enzymes Alliance. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total amount of €580 million, of which €80 million to cover commitments under the Group’s share-based compensation plans and €500 million to reduce its issued...

SIKA ACQUIRES RENOWNED CONSTRUCTION CHEMICALS COMPANY IN QATAR Sika has acquired Gulf Additive Factory LLC in the State of Qatar. The company manufactures a wide range of construction chemical products and has a strong standing in the fast-growing Qatar construction market. The acquisition strengthens Sika’s foothold in the country and provides exciting opportunities for further expansion. Gulf Additive Factory LLC (GAF) is renowned for its high-quality solutions and profound technical expertise. An extensive product range, including concrete admixtures, mortars, flooring, waterproofing and facade systems (EIFS: Exterior Insulation and Finish System) is manufactured in a strategically well-located production facility close to Doha. GAF’s large, modern manufacturing site will provide Sika with the opportunity to expand and drive growth...

The Supervisory Board of AS Harju Elekter Group decided to increase the share capital of the company by 17,010 euros by issuing new ordinary shares. The increase in the share capital is due to the need to issue new shares to the management board members and key personnel of Harju Elekter and its subsidiaries participating in the option program approved with the resolution of the general meeting on 29 April 2021. A total of 4 current and former employees of Harju Elekter participated in the share issue related to the implementation of the option program, who subscribed for a total of 27,000 shares for a total of 121,500 euros.  A total of 57,500 shares were not subscribed. Decisions of the Supervisory Board of AS Harju Elekter Group:Harju Elekter’s share capital will be increased by a maximum of 17,010 euros, i.e., from 11,654,225.10...